It was shown that intratumoral delivery of MLKL mRNA stimulates anti-tumor immunity against neo-epitopes, a process that was dependent on CD8α+ DCs, which are proficient in antigen cross-presentation. This evidence concerns the gene CD8A and neoplasm.